Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy

This publication has 36 references indexed in Scilit:

• DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: I. In Vitro Pharmacological Characterization and Pharmacokinetic Properties
  The Journal of Pharmacology and Experimental Therapeutics, 2004
• Pharmacological characterisation of a rat model of incisional pain
  British Journal of Pharmacology, 2004
• Inhibition of guinea‐pig and human sensory nerve activity and the cough reflex in guinea‐pigs by cannabinoid (CB₂) receptor activation
  British Journal of Pharmacology, 2003
• Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models
  European Journal of Neuroscience, 2003
• Analgesic Effects of Cannabinoids: Sites and Mechanisms of Action
  Reviews in Analgesia, 2003
• CB cannabinoid receptor agonists: pain relief without psychoactive effects?
  Current Opinion in Pharmacology, 2002
• CB2 cannabinoid receptor-mediated peripheral antinociception
  Published by Wolters Kluwer Health ,2001
• New class of potent ligands for the human peripheral cannabinoid receptor
  Bioorganic & Medicinal Chemistry Letters, 1996
• Characterization of a rat model of incisional pain
  PAIN®, 1996
• Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
  Biochemical Pharmacology, 1973